|1.||Smith, Amos B: 3 articles (09/2013 - 10/2010)|
|2.||Trojanowski, John Q: 3 articles (09/2013 - 10/2010)|
|3.||Brunden, Kurt R: 3 articles (09/2013 - 10/2010)|
|4.||Ballatore, Carlo: 3 articles (09/2013 - 10/2010)|
|5.||Yao, Yuemang: 3 articles (09/2013 - 10/2010)|
|6.||Lee, Virginia M-Y: 3 articles (09/2013 - 10/2010)|
|7.||James, Michael J: 3 articles (09/2013 - 10/2010)|
|8.||Hannah, Alison L: 3 articles (12/2012 - 12/2007)|
|9.||Kavallaris, Maria: 3 articles (11/2011 - 07/2003)|
|10.||Hensley, Martee L: 2 articles (12/2012 - 08/2012)|
09/01/2001 - "One newly discovered PK/NRP product, epothilone D from Sorangium cellulosum, has shown great potential as an anti-tumor agent. "
12/01/2005 - "Patupilone (EPO906, epothilone B) and epothilone D (KOS-862) are in early phase I/II clinical studies in patients with a variety of solid tumors. "
09/18/2006 - "A novel reversed-phase high-performance liquid chromatographic (HPLC) method has been established for the determination of a newly developed anti-cancer agent desoxyepothilone B (dEpo B) in nude mice plasma. "
06/01/2004 - "Kosan and Roche are developing the microtubule inhibitor epothilone D (KOS-862 and NSC-703147), an analog of epothilone B for the potential treatment of cancer. "
12/22/1998 - "Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel."
|2.||Breast Neoplasms (Breast Cancer)
03/01/2008 - "Additionally, other members of the epothilone family, such as patupilone, ZK-EPO, BMS-310705, and KOS-862, have demonstrated efficacy against breast cancer in phase I clinical trials. "
04/01/2008 - "Other epothilones currently in clinical studies are KOS-862, patupilone, ZK-EPO, BMS-310705, and KOS-1584, which have all shown activity in patients with pretreated or resistant metastatic breast cancer."
12/01/2008 - "Other epothilones such as KOS-862, patupilone, ZK-EPO, BMS-310705, and KOS-1584 are being evaluated as therapy for patients with breast cancer, with promising preliminary data. "
04/01/2008 - "For those epothilones that have gone on to clinical development (epothilone B, ixabepilone, BMS-310705, ZK-EPO, KOS-862, and KOS-1584), preclinical investigations in breast cancer models are reviewed. "
|3.||Schizophrenia (Dementia Praecox)
08/01/2014 - "Neuronal transport defects of the MAP6 KO mouse - a model of schizophrenia - and alleviation by Epothilone D treatment, as observed using MEMRI."
08/01/2014 - "These defects are alleviated not only by neuroleptics, which are the gold standard molecules for the treatment of schizophrenia, but also by Epothilone D (Epo D), which is a microtubule-stabilizing molecule. "
|4.||Body Weight (Weight, Body)
07/26/2005 - "We compared the efficacy of Flu with the epothilone analog 12,13-desoxyepothilone B (dEpoB) in xenograft nonobese diabetic/severe combined immunodeficient mouse models with subcutaneous or disseminated MM. Flu caused tumor disappearance in RPMI 8226 subcutaneous xenografts after only five doses of the drug (20 mg/kg of body weight), with no sign of relapse after 100 d of observation. "
09/12/2013 - "Recent data reveal that the brain-penetrant MT-stabilizing agent, epothilone D (EpoD), improves cognitive function and decreases both neuron loss and tau pathology in transgenic mouse models of tauopathy. "
10/13/2010 - "Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy."
04/01/2011 - "Furthermore, certain epothilones cause an increase in CNS MT stabilization, with epothilone D demonstrating a favorable pharmacokinetic and pharmacodynamic profile which suggests this agent merits further study as a potential tauopathy drug candidate."
03/19/2013 - "Accordingly, MT-stabilizing drugs such as paclitaxel and epothilone D have been shown as possible therapies for AD and related tauopathies. "
|2.||epothilone B (EPO906)
|4.||Antipsychotic Agents (Antipsychotics)
|5.||desoxyepothilone B (epothilone D)
|6.||ixabepilone (BMS 247550)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)